Island Pharmaceuticals targets Mosquito-borne viruses with antiviral pipeline

Digital Asset Direct by Island Pharmaceuticals Ltd

Melbourne, Victoria | December 21, 2022 02:30 PM Eastern Standard Time

Island Pharmaceuticals Ltd (ASX:ILA) CEO David Foster joins Proactive to introduce the company's drug research and repurposing mission. Island is primarily focused on developing preventative or therapeutic drugs for viral infections such as dengue fever and other mosquito-borne diseases. Foster says there is no specific pharmaceutical treatment for dengue fever and the one vaccine that exists is available to a highly restricted audience — opening the door for the company's clinical pipeline.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com